RAF1 and cancer: Since BGB‐283 was shown to inhibit RAF dimer activity, we hypothesized that BGB‐283 could inhibit MEKi‐induced MEK phosphorylation and therefore improve the potency of the latter in inhibiting K‐RAS‐mutated cancer cells.